If you have been reading about PPARδ agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516, GW-501516, GW 501516, endurobol | Names vary in research and anti-doping documents. |
| Chemical class | Synthetic PPARδ agonist | Small-molecule nuclear receptor ligand. |
| CAS Registry Number | 317318-70-0 | Identifier commonly associated with GW501516. |
| Appearance | White to off-white powder | Typical for purified research material. |
| Solubility | Low in water; soluble in DMSO and ethanol | Organic solvents are common for laboratory stock solutions. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
=== Organoindium compounds === Organoindium compounds feature In–C bonds. Most are In(III) derivatives, but cyclopentadienylindium(I) is an exception. It was the first known organoindium(I) compound, and is polymeric, consisting of zigzag chains of alternating indium atoms and cyclopentadienyl complexes. Perhaps the best-known organoindium compound is trimethylindium, In(CH3)3, used to prepare certain semiconducting materials.
He began writing lyrics to his own instrumentals while Toufouti wrote to Thépegnier's. Thépegnier was no longer in the Île-de-France region when Saddiction was composed, so he and Chanut had to develop demos separately. The tracks were then finalised by Toufouti and Hanvic, who contributed their ideas and arrangements.
CP, Crude protein; NRC MR, National Research Council Minimal Requirement; NR, not required (taurine not an essential amino acid in the dog); NA, not adequate sample for analysis Amino acids measured on a mg/g DM basis The results demonstrated that all evaluated insects met the canine and feline MR for growth of the NRC for EAA and CP with exception to the black soldier fly in regards to taurine, where composition was lower than recommended.
=== Genetic counseling === TCS is inherited in an autosomal dominant manner and the penetrance of the affected gene is almost complete. Some recent investigations, though, described some rare cases in which the penetrance in TCS was not complete. Causes may be a variable expressivity, an incomplete penetrance or germline mosaicism. Only 40% of the mutations are inherited. The remaining 60% are a result of a de novo mutation, where a child has a new mutation in the responsible gene and did not inherit it from either parent. In the outcome of the disease, inter- and intrafamilial variability occurs. This suggests that when an affected child is born, it is important to investigate the parents to determine whether the affected gene is present, because the parent could have a mild form of the disease that has not been diagnosed. In this case, the risk of having another affected child is 50%. If the parents do not have the affected gene, the recurrence risk appears to be low. In following generations, the severity of the clinical symptoms increases.
Sources: en.wikipedia.org
== Economy and finances == After 1937, the economy of Aden continued to be largely dependent on the city's role as an entrepôt for east–west trade. During the course of 1955, 5,239 vessels called at Aden, making its harbour the second busiest in the world after New York. However, tourism declined over the last years of the Colony with the number of tourists landing dropping by 37% from 204,000 in 1952 to 128,420 in 1966. At the end of British rule in 1967, the main revenues of the Colony were the Port Trust with an annual gross revenue of £1.75 million (2014 prices: £28.4 million) and the BP refinery which made direct payments to the Aden Government of £1.135 million (2014 prices: £18.4 million). In 1956, Aden Colony had a revenue of £2.9 million (approximately £65 million in 2014 prices). This was equivalent to around £58 per capita, one of the highest per head revenue earners amongst Britain's smaller colonies behind only the Falkland Islands, Brunei and Bermuda. However, the benefit to the United Kingdom of this was tempered by their commitments to the Aden protectorates which had revenue per capita of only 2.5 pence (only 23p in 2014 prices). By the time British rule was ending the Federation of South Arabia, of which the Colony was a part, was receiving £12.6 million (£209 million in 2014) from the British government to support its 1966–67 Budget.
Other than for vision, the metabolic functions of vitamin A are mediated by all-trans-retinoic acid (RA). The formation of RA from retinal is irreversible. To prevent accumulation of RA it is oxidized and eliminated fairly quickly, i.e., has a short half-life. Three cytochromes catalyze the oxidation of retinoic acid. The genes for Cyp26A1, Cyp26B1 and Cyp26C1 are induced by high levels of RA, providing a self-regulating feedback loop.
==== Hypopharyngeal or base of tongue obstruction ==== Base-of-tongue advancement by means of advancing the genial tubercle of the mandible, tongue suspension, or hyoid suspension (aka hyoid myotomy and suspension or hyoid advancement) may help with the lower pharynx. Other surgery options may attempt to shrink or stiffen excess tissue in the mouth or throat, procedures done at either a doctor's office or a hospital. Small shots or other treatments, sometimes in a series, are used for shrinkage, while the insertion of a small piece of stiff plastic is used in the case of surgery whose goal is to stiffen tissues.
=== Vaccine skepticism and connection to autism === In 2009, Carrey wrote an article questioning the merits of vaccination and discussing its connection to autism for The Huffington Post. With former partner Jenny McCarthy, Carrey led a "Green Our Vaccines" march in Washington, D.C., to advocate for the removal of "toxic substances" from children's vaccines, out of a belief that children had received "too many vaccines, too soon, many of which are toxic". The rally was criticized by David Gorski, an American surgical oncologist on Science-Based Medicine blog, for being anti-vaccine and not "pro-safe vaccine", and by Steven Parker on the WebMD website for being "irresponsible". In 2009, the couple appeared on Larry King Live to discuss autism. Carrey stated that he believes autism "is preventable and treatable," and that "it's still shocking to see how many people are ignoring this information." Carrey suggested rising autism rates was a warning about the medical industry, stating: "There's an autistic child on every block ... Autism is the canary in the coal mine. I believe that it's telling us that this vaccine program is imbalanced." On July 1, 2015, after the signing of a new vaccination law, Carrey called California governor Jerry Brown a "corporate fascist" who was "poisoning" children by enacting the vaccination requirements. The law disallowed religious and philosophical reasons for exemption from vaccination.
== Bibliography == Alt-Kutscha : vol.1 Archived 2020-01-27 at the Wayback Machine Arlt, Robert; Hiyama, Satomi (2013). "Fruits of Research on the History of Central Asian Art in Berlin: The Identification of Two Sermon Scenes from Kizil Cave 206 (Fußwaschungs- höhle)". Indo-Asiatische Zeitschrift (Berlin) 17: 16–26. Beckwith, Christopher (1993). The Tibetan Empire in Central Asia: A History of the Struggle for Great Power Among Tibetans, Turks, Arabs, and Chinese During the Early Middle Ages. Princeton University Press. ISBN 0-691-02469-3. Beckwith, Christopher I. (2009). Empires of the Silk Road: A History of Central Eurasia from the Bronze Age to the Present. Princeton University Press. ISBN 978-0-691-13589-2. Grousset, René (1970). The Empire of the Steppes: A History of Central Asia. Rutgers University Press. ISBN 978-0-8135-1304-1. Grünwedel, Albert (1912). Altbuddhistische Kultstätten in Chinesisch-Turkistan: Bericht über archäologische Arbeiten von 1906 bis 1907 bei Kuča, Qarašahr und in der Oase Turfan. Berlin: Arthur-Baessler-Institut. Doi:10.20676/00000191. Hopkirk, Peter (1984). Foreign devils on the silk road : the search for the lost cities and treasures of Chinese Central Asia. Amherst: University of Massachusetts Press. ISBN 9780870234354. Hiyama, Satomi 檜山智美 (2013) Study on the first-style murals of Kucha: Analysis of some motifs related to the Hephthalite's period クチャの第一樣式壁畫に見られるエフタル期のモチーフについて (“Kucha no daiichi yōshiki hekiga ni mirareru Efutaru ki no mochīfu ni tsuite”).
Sources: en.wikipedia.org
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.
No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.
Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.